MOLN · Nasdaq · ·
下次财报:2026年10月29日
US$4.300.0%9月25日 收盘
Molecular Partners AG 预定于 2026年10月29日发布下一份财报。日期来自 Nasdaq 财报日历,公司有时会调整。
截至 2025年6月30日 的季度,与去年同季度相比。
| 指标 | 截至该日的 3 个月2025年6月30日 | 截至该日的 3 个月2023年9月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$1.9M | US$3M | -38.96% |
| 自由现金流 | -US$12M | -US$15.9M | +25.05% |
这些是单季度数字,不是滚动一年——本站其他地方的数字覆盖十二个月,会大得多。季节性业务在两者之间摆动很大:ServiceNow 在十二月季度赚 20 亿美元自由现金流,在六月季度只有 5 亿。
对比对象是去年同一季度,而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据,那是我们没有的授权数据——而搞错它比不提更糟。
暂无 Molecular Partners AG 的业绩电话会文字记录。
“The first half of 2026 was marked by strong execution across our pipeline. With MP0712, a DLL3-targeting Radio-DARPin, we have treated the first patients in our SCLC trial, and dose escalation in the Phase 1/2a study is progressing as planned. To further strengthen our Radio pipeline, we selected CD70 as our next target, which will be evaluated using an isotope-agnostic approach. Backed by a strong balance sheet that funds operations into late 2027, we remain focused on delivering key value-driving milestones, including initial clinical data from MP0712 later this year and continued advancement of our pipeline,”
逐字引自公告,且只在文件将其归于具名人士时才展示。
Molecular Partners AG (SIX, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of medicines known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including radiopharmaceuticals for targeted alpha therapy and logic-gated, next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA.
公司自己的描述,取自公告末尾。
引述和公司简介来自 Molecular Partners AG 于 2026年8月25日 随业绩提交的 6-K 文件;表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。